New inhaled therapy for cystic fibrosis shows early promise

NCT ID NCT03375047

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested an inhaled drug called MRT5005 in 42 adults with cystic fibrosis. The goal was to check safety and see if it could improve lung function. Participants received either the drug or a placebo by nebulizer. The study is completed, and results will help decide if larger trials are warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MRT5005 (a drug given by inhalation)
What this could lead to: If successful, this could point toward a new inhaled treatment to improve lung function in people with cystic fibrosis.
What could go wrong: This is an early phase 1/2 trial with only 42 participants, so results may not confirm effectiveness or safety for wider use. The drug may cause side effects or fail to show meaningful benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYSTIC FIBROSIS

Contacts and locations

Locations

Johns Hopkins University

Baltimore, Maryland, 21287, United States
Maine Medical Center

Portland, Maine, 04102, United States
National Jewish Health

Denver, Colorado, 80206, United States
Nationwide Children's Hospital

Columbus, Ohio, 43205, United States
New Orleans Center for Clinical Research

Knoxville, Tennessee, 37920, United States
Northwestern University

Chicago, Illinois, 60611, United States
Oregon Health and Sciences University

Portland, Oregon, 97239, United States
University Hospitals

Cleveland, Ohio, 44106, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35233, United States
University of Cincinnati

Cincinnati, Ohio, 45267, United States
University of Florida

Gainesville, Florida, 32610, United States
University of Indiana

Indianapolis, Indiana, 46202, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
University of Utah

Salt Lake City, Utah, 84132, United States
Virginia Commonwealth University

Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.